Abstract 797TiP
Background
Surgery is the primary treatment for advanced endometrial cancer. Patients with no visible lesions have a better prognosis. Conventional preoperative neoadjuvant chemotherapy does not achieve a satisfactory R0 rate. The NCCN Guidelines for Uterine Neoplasms indicates that the incorporation of immunotherapy into the initial treatment regimen (carboplatin/paclitaxel) for advanced or recurrent endometrial cancer markedly enhances patient outcomes, irrespective of MMR status. This study aims to assess the efficacy of tislelizumab in conjunction with carboplatin/paclitaxel as a neoadjuvant treatment for advanced endometrial cancer. It is hypothesised that this treatment will improve the surgical R0 rate and reduce distant metastasis and disease recurrence in this patient population.
Trial design
This is a prospective, open-label, multicentre, single-arm study that aims to enroll 20 patients with previously untreated 2023 FIGO staging for endometrial cancer (III-IVb). Patients will receive tislelizumab (200 mg) in combination with carboplatin (AUC5)/paclitaxel (175 mg/m2) every three weeks, for two to four cycles. The number of treatment cycles may be adjusted by the investigator based on clinical practice. Surgery will be performed after neoadjuvant therapy achieves complete response (CR), partial response (PR), or stable disease (SD). Patients will receive maintenance therapy based on the investigator's choice. The primary endpoint of the study is the R0 rate. Secondary observational endpoints include pathological complete response (pCR)%, objective response rate (ORR), recurrence-free survival (RFS), progress-free survival (PFS), overall survival (OS), and safety. Adverse events are monitored according to the NCI CTCAE, Version 5.0. The estimated study duration is 18 months.
Clinical trial identification
NCT06363708.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
792P - The differences in immunogenicity of TP53 mutated endometrial-, high-grade serous ovarian- and triple negative breast carcinomas
Presenter: Alain Zeimet
Session: Poster session 02
793TiP - A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
Presenter: Domenica Lorusso
Session: Poster session 02
795TiP - A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors
Presenter: Isabelle Ray-Coquard
Session: Poster session 02
796TiP - Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS)
Presenter: Junhwan Kim
Session: Poster session 02
798TiP - Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy: SOPRANO trial
Presenter: Susana Banerjee
Session: Poster session 02
856P - Safety of neoadjuvant PARP inhibitor and immunotherapy in locally advanced HPV-negative head and neck squamous cell carcinoma (PRIME H&N Study)
Presenter: Luigi Lorini
Session: Poster session 02
857P - Safety and efficacy of neoadjuvant immunochemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial
Presenter: Jing Yan
Session: Poster session 02
Resources:
Abstract
858P - Preoperative neoadjuvant chemoimmunotherapy for locally advanced head and neck squamous cell carcinoma patients: A prospective, single-arm, phase II clinical study
Presenter: Ping Han
Session: Poster session 02